Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence P Carter

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2004
Discriminative stimulus effects of gamma-hydroxybutyrate in pigeons: role of diazepam-sensitive and -insensitive GABA(A) and GABA(B) receptorsWouter Koek, Lauren R Flores, Lawrence P Carter, et al.
Human Psychopharmacology|November 24, 2022
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trialFrederick Vinckenbosch, Gert Jan Lammers, Sebastiaan Overeem, et al.
Sleep Medicine|June 17, 2017
Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutesChad Ruoff, Richard K Bogan, Helen Emsellem, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
A tertiary alcohol analog of gamma-hydroxybutyric acid as a specific gamma-hydroxybutyric acid receptor ligandHuifang Wu, Nick Zink, Lawrence P Carter, et al.
Drug and Alcohol Dependence|March 17, 2005
Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV)Lawrence P Carter, Weibin Chen, Huifang Wu, et al.
CNS Drugs|June 27, 2020
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled TrialYves Dauvilliers, Colin Shapiro, Geert Mayer, et al.
Chest|November 25, 2018
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal StudyPatrick J Strollo, Jan Hedner, Nancy Collop, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2018
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled TrialPaula K Schweitzer, Russell Rosenberg, Gary K Zammit, et al.
Annals of Neurology|January 30, 2019
A randomized study of solriamfetol for excessive sleepiness in narcolepsyMichael J Thorpy, Colin Shapiro, Geert Mayer, et al.
Drug and Alcohol Dependence|September 22, 2009
Case histories in pharmaceutical risk managementCynthia G McCormick, Jack E Henningfield, J David Haddox, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2004
Discriminative stimulus effects of gamma-hydroxybutyrate in pigeons: role of diazepam-sensitive and -insensitive GABA(A) and GABA(B) receptorsWouter Koek, Lauren R Flores, Lawrence P Carter, et al.
Human Psychopharmacology|November 24, 2022
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trialFrederick Vinckenbosch, Gert Jan Lammers, Sebastiaan Overeem, et al.
Sleep Medicine|June 17, 2017
Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutesChad Ruoff, Richard K Bogan, Helen Emsellem, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
A tertiary alcohol analog of gamma-hydroxybutyric acid as a specific gamma-hydroxybutyric acid receptor ligandHuifang Wu, Nick Zink, Lawrence P Carter, et al.
Drug and Alcohol Dependence|March 17, 2005
Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV)Lawrence P Carter, Weibin Chen, Huifang Wu, et al.
CNS Drugs|June 27, 2020
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled TrialYves Dauvilliers, Colin Shapiro, Geert Mayer, et al.
Chest|November 25, 2018
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal StudyPatrick J Strollo, Jan Hedner, Nancy Collop, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2018
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled TrialPaula K Schweitzer, Russell Rosenberg, Gary K Zammit, et al.
Annals of Neurology|January 30, 2019
A randomized study of solriamfetol for excessive sleepiness in narcolepsyMichael J Thorpy, Colin Shapiro, Geert Mayer, et al.
Drug and Alcohol Dependence|September 22, 2009
Case histories in pharmaceutical risk managementCynthia G McCormick, Jack E Henningfield, J David Haddox, et al.
Pageof 5